Anti-TNF alpha in the treatment of ulcerative colitis: A valid approach for organ-sparing or an expensive option to delay surgery?

Table 2 Rate of overall post-operative morbidity and post-operative infectious complications in patients pre-operatively treated with Infliximab

Ref.	RCT	Pts (IFX vscontrol ) (n)	PO morbidity(IFX vs control )	P value	PO infectious complications (IFX vs control)	P value
Schluender et al[64]	N	17 vs 134	36% vs 28%	> 0.05	18% vs 8%	> 0.05
Selvasekar et al[62]	N	47 vs 254	62% vs 49%	0.10	28% vs 10%	< 0.01
Mor et al[63]	N	46 vs 46	34.8% vs 15.2%	0.004	21.7% vs 2.2%	0.011
Ferrante et al[65]	N	22 vs 119	11.1% vs 28.6%	> 0.05	9% vs 24%	0.161
Gainsbury et al[66]	N	29 vs 52	44.8% vs 44.2%	0.96	17.2% vs 26.9%	0.32
Rizzo et al[67]	N	16 vs 22	37.5% vs 22.7%	> 0.05	18.7% vs 18.2%	> 0.05

RCT: Randomized controlled trial; Pts: Patients; PO: Post-operative; IFX: Infliximab; Y: Yes.